Zepbound beats Wegovy rival in 1st head-to-head weight loss study
Global News
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 kilograms). That’s according to the study funded by Lilly, which was published Sunday in the New England Journal of Medicine.
Both drugs are part of a new class of medications that work by mimicking hormones in the gut and brain that regulate appetite and feelings of fullness. But tirzepatide targets two such hormones, known as GLP-1 and GIP, while semaglutide targets GLP-1 alone, said Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine.
“Two drugs together can produce better weight loss,” said Aronne, who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.
While tirzepatide won out in what Aronne said many view as “a drag race of efficacy,” both are important tools for treating obesity, which affects about 40 per cent of American adults.
“The point of these medications is to improve health,” he said. “The majority of people won’t need the most effective medication.”
The trial included 751 people from across the U.S. who were overweight or had obesity and at least one other weight-related health problem, but not diabetes. Participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 milligrams.
By the end of the trial, those who took Zepbound lost about 20 per cent of their body weight on average, compared with a nearly 14 per cent loss for those who took Wegovy. The tirzepatide group trimmed about 7 inches (17.8 centimeters) from their waist circumference, compared to about five inches (12.7 centimeters) with semaglutide. In addition, nearly 32 per cent of people taking Zepbound lost at least a quarter of their body weight, compared to about 16 per cent of those taking Wegovy, the study found.
Some experts say that a cyberwar through 'proxies' may be the next stage of the Iran war, with civilian infrastructure also coming under threat.
The study is being billed by the university as "the first to study a wide range of factors which link ADHD symptoms and mental ill health symptoms over time."
The group says MAGA Energy hasn't paid its lease for three years, and therefore the company is no longer allowed on their land in Edmonton.
The analysis by the Canadian Climate Institute says oilsands producers will pay an average of about 50 cents per oil barrel, if the minimum carbon price rises to $130 per tonne.
Between November 29 and February 27, authorities recorded 406 outbreaks of bird flu in domestic birds in 32 European countries and 2,108 outbreaks in wild birds, they said.
Dr. Michael Domeier, director of the Marine Conservation Science Institute, told Global News that they tag the adult females as they are the most interesting.
Regina’s recycling contamination is currently triple the limit and city is urging resident to change sorting habits now to avoid citywide fines and higher resident fees.
The study found that higher ultra-processed food intake at age three years was associated with adverse behavioural and emotional symptoms at age five years.
Edmonton's single-use waste rules were controversial and unpopular when introduced in 2023 — but new data shows the changes are having the intended effect of reducing garbage.
Carney's speech to Australia's parliament highlighted a soon-to-launch Canadian low earth orbit satellite network that experts say could soon compete with Elon Musk's Starlink.
The Pentagon said in a statement Thursday that it has “officially informed Anthropic leadership the company and its products are deemed a supply chain risk, effective immediately.”
Opioid overdose deaths in Canada are falling, but there's growing concerns on a certain veterinary tranquilizer being cut into fentanyl and other opioids.
The product is being recalled in Alberta, British Columbia, Manitoba, Ontario, Quebec and Saskatchewan due to 'undeclared almonds' being found.